Search clinical trials for: AZD8853

Total 68 results

AstraZeneca
Quotient Sciences

Completed

A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833

Healthy Volunteers

United Kingdom
AstraZeneca

Active, not recruiting

A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer

ER+ HER2- Advanced Breast Cancer

Japan
AstraZeneca
Parexel

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.

Hypercholesterolemia

United States
AstraZeneca
Parexel

Completed

A Study to Evaluate the Safety, Tolerability and Absorption to the Blood After Administration of Single and Multiple Doses of AZD8154 in Healthy Participants.

Asthma

Germany
AstraZeneca
Parexel

Terminated

To Assess the Pharmacokinetics, Safety, and Tolerability of AZD8233 in Participants With Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and Healthy Participants.

End Stage Renal Disease

Poland
AstraZeneca
Parexel

Terminated

Evaluation of AZD8154 Concentrations in Blood

Asthma

Germany
AstraZeneca

Not yet recruiting

LTFU for All Cell and Gene Therapy Studies (LOCUS)

Hepatocellular Carcinoma | Prostate Cancer

United States
AstraZeneca

Terminated

AZD8683 Multiple Dose Study in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients

COPD

United Kingdom
AstraZeneca
Quintiles, Inc.

Terminated

A Study to Assess Safety, Tolerability and Pharmacokinetics of of AZD6553 in Healthy Volunteers and Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United Kingdom
AstraZeneca

Completed

Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

Hepatic Impairment

United States, Bulgaria, Slovakia
AstraZeneca

Completed

A Study to Investigate the Impact of Dose and Dosing Frequency of AZD8848 on the Response on Biomarkers

Healthy Volunteers

Sweden
AstraZeneca

Completed

The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Poland
AstraZeneca
ImaginAb, Inc.

Terminated

A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours

Carcinoma, Non-Small-Cell Lung | Urinary Bladder Neoplasms | Colorectal Cancer

United States, Canada
AstraZeneca
Parexel

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia

Dyslipidemia

United States
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Inhaled AZD8683

Healthy

United Kingdom
AstraZeneca

Active, not recruiting

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (SERENA-1)

ER+ HER2- Advanced Breast Cancer

United States, Spain, United Kingdom
AstraZeneca

Recruiting

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Gastric Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Adenocarcinoma | Gastro-esophageal Junction Cancer

Korea, Republic of, United States, Japan, Taiwan, China, United Kingdom, Netherlands
AstraZeneca

Completed

A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer (SERENA-3)

HER2-negative Breast Cancer

Mexico, United Kingdom, Georgia
AstraZeneca
Parexel

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects

Chronic Obstructive Pulmonary Disease

United Kingdom
AstraZeneca
Parexel; Covance; The Doctors Laboratory; Industrias Farmacéuticas Almirall S.A.

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects

Chronic Obstructive Pulmonary Disease - COPD

United Kingdom
AstraZeneca

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants.

Heathy Participants

Japan
AstraZeneca

Completed

A Study of Tor Kinase Inhibitor in Advanced Tumors

Solid Tumors

United States, France, United Kingdom
AstraZeneca

Completed

Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects

Asthma (Part 1) | COPD (Part 2)

United Kingdom
AstraZeneca

Completed

Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

Advanced Solid Malignancies | Breast Cancer - ER+, HER2 - | Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation

United States, United Kingdom
AstraZeneca

Completed

Study to Investigate the Safety and Tolerability of AZD8848 in Butyrylcholinesterase Deficient Subjects

Butyrylcholinesterase Deficiency

Denmark
AstraZeneca

Withdrawn

A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD8683 When Administered in Different Ways

Healthy
AstraZeneca
Parexel

Completed

Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871

Chronic Obstructive Pulmonary Disease COPD

Germany, United Kingdom
AstraZeneca

Completed

A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia (SOLANO)

Hyperlipidaemia

Denmark, Netherlands, Spain, Czechia, United States, Slovakia, Hungary, Poland
AstraZeneca

Completed

Tolerability/PoP Study in Allergic Rhinitis After Intranasal Administration of AZD8848

Allergic Rhinitis

Sweden
AstraZeneca

Completed

A Study of AZD8233 in Participants With Dyslipidemia

Dyslipidaemia

Denmark, United States, Slovakia
AstraZeneca

Completed

AZD8848 Single Ascending Dose Study

Healthy

United Kingdom
AstraZeneca

Completed

The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen

Allergic Asthma

United Kingdom
AstraZeneca

Completed

Tolerability/Safety of Intranasal AZD8848 in Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season (SAD)

Healthy | Allergic Rhinitis

Sweden
AstraZeneca

Completed

AZD8683 Single Ascending Dose Study

Healthy Volunteers

United States
AstraZeneca

Completed

AZD9833 China PK Study (AZD9833)

ER+, HER2-, Metastatic Breast Cancer

China
AstraZeneca

Completed

Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055

Cancer | Solid Tumors | Advanced Solid Malignancies

Japan
AstraZeneca

Withdrawn

Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours

Cancer | Advanced Solid Tumours | Lymphomas
AstraZeneca

Recruiting

A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma (ATHENA)

Hepatocellular Carcinoma

United States, Korea, Republic of
National Cancer Institute (NCI)

Completed

AZD8055 for Adults With Recurrent Gliomas

Glioblastoma Multiforme | Malignant Glioma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma | Brainstem Glioma

United States
AstraZeneca

Completed

Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients

Cancer | Advanced Hepatocellular Carcinoma

Korea, Republic of, Hong Kong
AstraZeneca
Quotient Sciences

Completed

A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833

ER-positive, HER2-negative Breast Cancer

United Kingdom
AstraZeneca
Parexel

Withdrawn

A Study to Evaluate the Effect of AZD8154 Administered Via Nebulizer Once Daily in Subjects With Mild Allergic Asthma Challenged With an Inhaled Allergen

Asthma

Canada
AstraZeneca

Completed

Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants

Corona Virus Disease

United States
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses AZD8848 in Healthy Subjects

Healthy Subjects | Safety, | Tolerability,

United Kingdom
AstraZeneca

Completed

Efficacy Study in Allergic Rhinitis Patients After Intranasal Administration of AZD8848

Allergic Rhinitis

Sweden
AstraZeneca
Parexel

Completed

A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.

Chronic Obstructive Pulmonary Disease

Germany, United Kingdom
AstraZeneca

Completed

A Study of AZD8233 in Participants With Dyslipidemia. (HAYATE)

Dyslipidemia

Japan
AstraZeneca

Terminated

A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19 (ENDURE)

Coronavirus Disease 2019 (COVID-19)

United States
AstraZeneca

Completed

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Lymphoma | Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Malignant Solid Tumors

United States, Canada
AstraZeneca

Completed

Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults (TACKLE)

COVID-19

United States, Spain, United Kingdom, Brazil, Germany, Ukraine, Japan, Italy, Poland, Russian Federation, Mexico, Czechia, Argentina, Hungary, Peru

3

Subscribe